Journal of University of Anbar for Pure Science

Abstract

SAR-COV2 is still a pressing issue, 219M people were infected and more than 4.5M lost their lives. The majority of antiviral and inflammatory therapies could only provide a supportive role in treating a limited number of COVID cases. This review investigates the available vaccines in terms of their safety and efficiency in fighting the virus. Seven vaccines are similar in their side effects to other influenza vaccines and their necessity to a booster dose. Although that several technologies have been used to manufacture the vaccine, mRNA vaccines clearly show a high protection rate touched 90% specially in severe and hospitalization cases prevention. Among all available vaccines, Pfizer vaccine is an exception as it granted the full approval to be used in people age 16 and under till five years.